Study defines early-onset cirrhosis caused by fatty liver disease
Researchers at University of California San Diego School of Medicine have published the first study to define early-onset…
Combination therapy overcomes ferroptosis resistance in β-catenin-mutant hepatocellular carcinoma
Background and aims The aberrant activation of the mTOR pathway and its crosstalk with other signaling cascades represent…
Daily tomatoes lowered a key marker of liver fat in MASLD trial
A six-week tomato-rich diet outperformed a tomato-free diet on an important marker of hepatic steatosis, pointing to a…
Occult hepatitis B mutations drive liver cancer growth via Akt mTOR pathway
Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar of…
AI model predicts effective immunotherapy combinations for liver cancer
Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of…
Integrating gene signatures and multi omics improves liver cancer treatment
Hepatocellular carcinoma (HCC) remains highly fatal due to late diagnosis and scarce early biomarkers. Multi‑omics and liquid biopsy…
Microbiome science merges with oncology for better cancer treatments
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the resident microbiota, to…
Machine learning model predicts liver cancer risk with high accuracy
Bottom line: A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test…
EVA1A regulates fatty acid transporter CD36 in fatty liver disease
Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated…
Researchers develop new score to predict the risk of liver cancer
Researchers led by Xian-Yang Qin at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have developed…
Study identifies key molecular and clinical biomarkers for MASLD
Background and aims The causal biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) and their clinical value remain…